Citius Oncology (CTOR) Competitors

$0.84 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.84 0.00 (-0.46%)

As of 05/22/2026 06:25 PM Eastern

CTOR vs. NAGE, LENZ, AMRN, REPL, and AKBA

Should you buy Citius Oncology stock or one of its competitors? MarketBeat compares Citius Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Citius Oncology include Niagen Bioscience (NAGE), LENZ Therapeutics (LENZ), Amarin (AMRN), Replimune Group (REPL), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry.

How does Citius Oncology compare to Niagen Bioscience?

Citius Oncology (NASDAQ:CTOR) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

In the previous week, Niagen Bioscience had 2 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for Niagen Bioscience and 0 mentions for Citius Oncology. Niagen Bioscience's average media sentiment score of 1.00 beat Citius Oncology's score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Oncology	Neutral
Niagen Bioscience	Positive

Citius Oncology has a beta of 3.56, indicating that its stock price is 256% more volatile than the broader market. Comparatively, Niagen Bioscience has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market.

Niagen Bioscience has a net margin of 14.29% compared to Citius Oncology's net margin of 0.00%. Niagen Bioscience's return on equity of 22.68% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Niagen Bioscience	14.29%	22.68%	16.23%

Niagen Bioscience has higher revenue and earnings than Citius Oncology. Citius Oncology is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Niagen Bioscience	$129.42M	2.25	$17.38M	$0.21	17.43

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 7.8% of Citius Oncology shares are held by insiders. Comparatively, 10.0% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Citius Oncology currently has a consensus target price of $6.00, indicating a potential upside of 614.37%. Niagen Bioscience has a consensus target price of $14.67, indicating a potential upside of 300.73%. Given Citius Oncology's higher possible upside, research analysts plainly believe Citius Oncology is more favorable than Niagen Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Niagen Bioscience	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Niagen Bioscience beats Citius Oncology on 12 of the 15 factors compared between the two stocks.

How does Citius Oncology compare to LENZ Therapeutics?

Citius Oncology (NASDAQ:CTOR) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings.

Citius Oncology has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 7.8% of Citius Oncology shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Citius Oncology has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
LENZ Therapeutics	$19.09M	12.40	-$82.13M	-$3.60	N/A

Citius Oncology has a beta of 3.56, suggesting that its stock price is 256% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market.

Citius Oncology currently has a consensus target price of $6.00, indicating a potential upside of 614.37%. LENZ Therapeutics has a consensus target price of $29.80, indicating a potential upside of 294.70%. Given Citius Oncology's higher possible upside, equities analysts clearly believe Citius Oncology is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, LENZ Therapeutics had 2 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for LENZ Therapeutics and 0 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.00 equaled LENZ Therapeutics'average media sentiment score.

Company	Overall Sentiment
Citius Oncology	Neutral
LENZ Therapeutics	Neutral

Summary

Citius Oncology beats LENZ Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Citius Oncology compare to Amarin?

Amarin (NASDAQ:AMRN) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, media sentiment, dividends, valuation and profitability.

22.3% of Amarin shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 4.2% of Amarin shares are held by company insiders. Comparatively, 7.8% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Amarin had 2 more articles in the media than Citius Oncology. MarketBeat recorded 2 mentions for Amarin and 0 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 0.00 beat Amarin's score of -0.05 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Amarin	Neutral
Citius Oncology	Neutral

Amarin presently has a consensus target price of $12.00, suggesting a potential downside of 16.84%. Citius Oncology has a consensus target price of $6.00, suggesting a potential upside of 614.37%. Given Citius Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Citius Oncology is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Amarin has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.56, suggesting that its share price is 256% more volatile than the broader market.

Citius Oncology has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
Citius Oncology	N/A	-99.47%	-42.16%

Citius Oncology has lower revenue, but higher earnings than Amarin. Amarin is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$213.65M	1.42	-$38.80M	-$0.65	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Summary

Citius Oncology beats Amarin on 11 of the 15 factors compared between the two stocks.

How does Citius Oncology compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Citius Oncology's return on equity of -99.47% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-102.69%	-72.22%
Citius Oncology	N/A	-99.47%	-42.16%

Replimune Group currently has a consensus price target of $4.75, suggesting a potential downside of 3.26%. Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 614.37%. Given Citius Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Citius Oncology is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	4 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.60
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Replimune Group has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.56, suggesting that its stock price is 256% more volatile than the broader market.

In the previous week, Replimune Group had 4 more articles in the media than Citius Oncology. MarketBeat recorded 4 mentions for Replimune Group and 0 mentions for Citius Oncology. Replimune Group's average media sentiment score of 0.00 equaled Citius Oncology'saverage media sentiment score.

Company	Overall Sentiment
Replimune Group	Neutral
Citius Oncology	Neutral

Citius Oncology is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 5.2% of Replimune Group shares are held by insiders. Comparatively, 7.8% of Citius Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Citius Oncology beats Replimune Group on 9 of the 12 factors compared between the two stocks.

How does Citius Oncology compare to Akebia Therapeutics?

Citius Oncology (NASDAQ:CTOR) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Citius Oncology has a beta of 3.56, meaning that its share price is 256% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

In the previous week, Akebia Therapeutics had 1 more articles in the media than Citius Oncology. MarketBeat recorded 1 mentions for Akebia Therapeutics and 0 mentions for Citius Oncology. Akebia Therapeutics' average media sentiment score of 0.37 beat Citius Oncology's score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Oncology	Neutral
Akebia Therapeutics	Neutral

Citius Oncology currently has a consensus target price of $6.00, suggesting a potential upside of 614.37%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 357.52%. Given Citius Oncology's stronger consensus rating and higher probable upside, research analysts clearly believe Citius Oncology is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 7.8% of Citius Oncology shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Citius Oncology has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Akebia Therapeutics' return on equity of -62.72% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Akebia Therapeutics has higher revenue and earnings than Citius Oncology. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Citius Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Akebia Therapeutics	$236.20M	1.16	-$5.34M	-$0.08	N/A

Summary

Akebia Therapeutics beats Citius Oncology on 8 of the 15 factors compared between the two stocks.

Get Citius Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTOR vs. The Competition

Export

Metric	Citius Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$78.09M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-1.79	18.74	20.99	25.66
Price / Sales	N/A	323.98	560.30	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	2.21	7.09	10.41	7.14
Net Income	-$24.76M	$24.45M	$3.57B	$335.98M
7 Day Performance	1.41%	6.38%	6.41%	4.15%
1 Month Performance	-4.24%	2.43%	3.55%	2.54%
1 Year Performance	-7.70%	62.98%	34.12%	35.06%

Citius Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTOR Citius Oncology	1.8593 of 5 stars	$0.84 flat	$6.00 +614.4%	-7.7%	$78.09M	N/A	N/A	N/A	Gap Down
NAGE Niagen Bioscience	4.0674 of 5 stars	$3.85 -3.3%	$14.67 +281.0%	-63.0%	$316.98M	$129.42M	18.33	120	Positive News Gap Up
LENZ LENZ Therapeutics	2.309 of 5 stars	$7.91 -20.8%	$31.00 +291.9%	-73.2%	$313.23M	$20.99M	N/A	110	High Trading Volume
AMRN Amarin	0.7403 of 5 stars	$14.95 -0.5%	$12.00 -19.7%	+29.9%	$312.48M	$213.65M	N/A	360	Negative News
REPL Replimune Group	1.2716 of 5 stars	$4.09 +9.4%	$4.75 +16.1%	-41.2%	$308.82M	N/A	N/A	210	Upcoming Earnings Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTOR) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Citius Oncology (CTOR) Competitors

CTOR vs. NAGE, LENZ, AMRN, REPL, and AKBA

How does Citius Oncology compare to Niagen Bioscience?

Summary

How does Citius Oncology compare to LENZ Therapeutics?

Summary

How does Citius Oncology compare to Amarin?

Summary

How does Citius Oncology compare to Replimune Group?

Summary

How does Citius Oncology compare to Akebia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Citius Oncology (CTOR) Competitors

CTOR vs. NAGE, LENZ, AMRN, REPL, and AKBA

How does Citius Oncology compare to Niagen Bioscience?

Does the media refer more to CTOR or NAGE?

Which has more risk & volatility, CTOR or NAGE?

Is CTOR or NAGE more profitable?

Which has higher valuation & earnings, CTOR or NAGE?

Do insiders and institutionals believe in CTOR or NAGE?

Do analysts rate CTOR or NAGE?

Summary

How does Citius Oncology compare to LENZ Therapeutics?

Is CTOR or LENZ more profitable?

Do institutionals & insiders have more ownership in CTOR or LENZ?

Which has better valuation & earnings, CTOR or LENZ?

Which has more volatility and risk, CTOR or LENZ?

Do analysts prefer CTOR or LENZ?

Does the media refer more to CTOR or LENZ?

Summary

How does Citius Oncology compare to Amarin?

Do insiders and institutionals hold more shares of AMRN or CTOR?

Does the media prefer AMRN or CTOR?

Do analysts recommend AMRN or CTOR?

Which has more risk & volatility, AMRN or CTOR?

Is AMRN or CTOR more profitable?

Which has stronger earnings and valuation, AMRN or CTOR?

Summary

How does Citius Oncology compare to Replimune Group?

Is REPL or CTOR more profitable?

Do analysts recommend REPL or CTOR?

Which has more volatility & risk, REPL or CTOR?

Does the media favor REPL or CTOR?

Which has better valuation and earnings, REPL or CTOR?

Do insiders & institutionals hold more shares of REPL or CTOR?

Summary

How does Citius Oncology compare to Akebia Therapeutics?

Which has more risk and volatility, CTOR or AKBA?

Does the media refer more to CTOR or AKBA?

Do analysts recommend CTOR or AKBA?

Do institutionals and insiders hold more shares of CTOR or AKBA?

Is CTOR or AKBA more profitable?

Which has stronger valuation & earnings, CTOR or AKBA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTOR vs. The Competition

Citius Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools